Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort.

OBJECTIVE To report the 10-year outcome of an inception cohort of patients with early rheumatoid arthritis (RA), the ESPOIR cohort, and predictors of outcome. METHODS From 2003 to 2005, 813 patients were included if they had early arthritis (< 6 months) with a high probability of RA and had never been prescribed DMARDs. Multivariate analysis was used to evaluate predictors of outcome. RESULTS In total, 521 (64.1%) RA patients were followed up for 10 years; 35 (4.3%) died which appears similar to the French general population. Overall, 480 (92.1%) patients received a DMARD; 174 (33.4%) received at least one biologic DMARD, 13.6% within 2 years. At year 10, 273 (52.4%) patients were in DAS28 remission, 40.1% in sustained remission, 14.1% in drug-free remission, 39.7% in CDAI remission. Half of the patients achieved a HAQ-DI < 0.5. SF-36 physical component and pain were well controlled. Structural progression was weak, with a mean change from baseline in modified Sharp score of 11.0 ± 17.9. Only 34 (6.5%) patients required major joint surgery. A substantial number of patients showed new comorbidities over 10 years. Positivity for ACPA was confirmed as a robust predictor of long-term outcome. CONCLUSIONS We report a very mild 10-year outcome of a large cohort of patients with early RA diagnosed in the early 2000s, which was much better than results for a previous cohort of patients who were recruited in 1993. This current favourable outcome may be related to more intensive care for real-life patients.

[1]  H. B. Hammer,et al.  Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. , 2020, RMD open.

[2]  T. Huizinga,et al.  Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: A longitudinal cohort study in the Netherlands , 2020, PLoS medicine.

[3]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[4]  S. Norton,et al.  Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis. , 2020, Seminars in arthritis and rheumatism.

[5]  T. Kvien,et al.  Trends in all-cause and cardiovascular mortality in patients with incident rheumatoid arthritis: a 20-year follow-up matched case-cohort study. , 2019, Rheumatology.

[6]  G. Kingsley,et al.  Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritis , 2019, BMC Rheumatology.

[7]  M. Lunt,et al.  Baseline patient reported outcomes are more consistent predictors of long-term functional disability than laboratory, imaging or joint count data in patients with early inflammatory arthritis: A systematic review , 2018, Seminars in arthritis and rheumatism.

[8]  M. Lunt,et al.  Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register , 2018, Annals of the rheumatic diseases.

[9]  A. Barton,et al.  Rheumatoid arthritis , 2018, Nature Reviews Disease Primers.

[10]  I. Hafström,et al.  Patients with Early Rheumatoid Arthritis in the 2000s Have Equal Disability and Pain Despite Less Disease Activity Compared with the 1990s: Data from the BARFOT Study over 8 Years , 2017, The Journal of Rheumatology.

[11]  S. Norton,et al.  Reductions in Radiographic Progression in Early Rheumatoid Arthritis Over Twenty‐Five Years: Changing Contribution From Rheumatoid Factor in Two Multicenter UK Inception Cohorts , 2017, Arthritis care & research.

[12]  Multireader assessment as an alternative to reference assessment to improve the detection of radiographic progression in a large longitudinal cohort of rheumatoid arthritis (ESPOIR) , 2017, RMD Open.

[13]  M. Abrahamowicz,et al.  Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population—closing the mortality gap , 2016, Annals of the rheumatic diseases.

[14]  M. Dougados,et al.  2016 update of the EULAR recommendations for the management of early arthritis , 2016, Annals of the rheumatic diseases.

[15]  G. Haugeberg,et al.  Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway , 2015, Arthritis Research & Therapy.

[16]  M. Dougados,et al.  Five-year Favorable Outcome of Patients with Early Rheumatoid Arthritis in the 2000s: Data from the ESPOIR Cohort , 2013, The Journal of Rheumatology.

[17]  P. Tugwell,et al.  American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. , 2011, Arthritis and rheumatism.

[18]  A. Silman,et al.  UvA-DARE (Digital Academic Repository) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative Aletaha, , 2010 .

[19]  Olivier Meyer,et al.  Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study , 2008, Arthritis Research & Therapy.

[20]  T. Pincus,et al.  Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. , 2005, Arthritis and rheumatism.

[21]  D. Symmons,et al.  The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study. , 2000, Rheumatology.